//
// file taut_standardise_default_smirks.H
// David Cosgrove
// AstraZeneca
// 8th September 2011
//
// Contains the default SMIRKS definitions for tautomer standardisation
// as defined by Pete Kenny all those years ago, and converted to SMIRKS
// by Andrew Leach.

#ifndef TAUT_STANDARDISE_DEFAULT_SMIRKS_H
#define TAUT_STANDARDISE_DEFAULT_SMIRKS_H

#include <string>

namespace DACLIB {

const std::string STAND_SMIRKS = "\n\
# Made into SMIRKS by AGL July 2011\n\
#  \n\
#  sbde_standardise.smt_v1.2                       PW Kenny 04-Oct-2005\n\
#\n\
#  SBDE structure standardisation SMARTS Version 1.2\n\
#\n\
#  These SMARTS were generated by making sbde_standardise.smt_v1.1\n\
#  SMARTS compatible with both Daylight and OEChem which differ in \n\
#  their use of the R and r descriptors.  \n\
#\n\
#  To be used with the sbde_standardise.vb_1.2 vector bindings.\n\
#\n\
#  The SMARTS definitions in this file are the property of \n\
#  AstraZeneca and must not be distributed or otherwise made \n\
#  available outside the Company\n\
#\n\
########################################################################\n\
#\n\
#  Sources:  \n\
#  	TautHet:  J Elguero et al, The Tautomerism of Heterocycles\n\
#                 Academic Press, 1976\n\
#\n\
#-------------------------------------------------------------------  \n\
#\n\
#  Convert hydrogen isotopes bound to oxygen or nitrogen to implicit \n\
#  hydrogen.  This is physically reasonable since these will exchange\n\
#  in an aqueous medium and isotopes will trash a number of\n\
#  computational packages.  Restricted this to heteroatoms because\n\
#  OEChem treats hydrogen atoms in chiral labels as explicit\n\
#\n\
#[N,n,O,S][#1]\n\
#Hyd 1 1\n\
#Bnd 1 2 0\n\
#AGL\n\
#[N,n,O,S:1][#1:2]>>[N,n,O,S:1][H] STAND_1\n\
#\n\
#  Discard  selected metals singly bonded to oxygen.  These\n\
#  relatively uncommon structural types are ocasionally encountered \n\
#  in supplier databases.  Bond breaking is not specified when the \n\
#  metal has been assigned a formal negative charge because this is\n\
#  generally as sign of a ghastly stucture (as found in Beilstein)      \n\
#  Also note explicit selection of 'bland' metals ensuring that\n\
#  potential nasties (e.g. thallium, silver, tin) remain with their\n\
#  structure for cleansing later.\n\
#   \n\
#[$BlandMet;-0]-[O,S]\n\
#Cul 1\n\
#Hyd 2 1\n\
#AGL\n\
[$BlandMet;-0]-[O,S:1]>>[H][*:1] STAND_2\n\
#\n\
#--------------------------------------------------------------------\n\
#\n\
#  De-salting and removal of other small fragments\n\
#\n\
#  The approach here is to delete explicitly defined fragments making\n\
#  sure that they do not constitute the entire molecule.\n\
#\n\
#  Fragments are either deleted entirely in a single step or\n\
#  converted to unconnected atoms to be mopped up later.  We \n\
#  deliberately don't de-salt perchlorates or nitrates so that \n\
#  these oxidising counter-ions remain visible.\n\
#\n\
#  Discard atoms lacking non-hydrogen connections\n\
#  This is done a the start in order to bias fragment\n\
#  deletion towards these smallest of fragments.  It is also\n\
#  done again at the end since part of the de-salting involves\n\
#  targetting molecules for destruction by breaking bonds to \n\
#  singly-linked atoms.  \n\
#\n\
#[$BlandMet,C,N,O,F,Cl,Br,I,2*,3*;D0;$Disconn]\n\
#Cul 1\n\
#AGL\n\
#[$BlandMet,C,N,O,F,Cl,Br,I,2*,3*;D0;$Disconn]>> STAND_3\n\
[$BlandMet&D0,$C_NO_CONNECTION,$N_NO_CONNECTION,$O_NO_CONNECTION,$HALIDE_NO_CONNECTION,2*,3*;$Disconn]>> STAND_3\n\
#\n\
#  Acids & anions\n\
#\n\
#[O;D1;$Disconn]C(=O)[$([CH3]),$(C(F)(F)F)]\n\
#Cul *\n\
#AGL\n\
#[O;D1;$Disconn]C(=O)[$([CH3]),$(C(F)(F)F)]>>  STAND_4\n\
[$O_ONE_CONNECTION;$Disconn]C(=O)[$([CH3]),$(C(F)(F)F)]>>  STAND_4\n\
#[O;D1;$Disconn][CH]=O\n\
#Cul *\n\
#[O;D1;$Disconn][CH]=O>>  STAND_5\n\
[$O_ONE_CONNECTION;$Disconn][CH]=O>>  STAND_5\n\
#[O;D1;$Disconn]S(=O)(=O)[$([CH3]),$([OD1]),$(C(F)(F)F)]\n\
#Cul *\n\
#[O;D1;$Disconn]S(=O)(=O)[$([CH3]),$([OD1]),$(C(F)(F)F)]>>  STAND_6\n\
[$O_ONE_CONNECTION;$Disconn]S(=O)(=O)[$([CH3]),$([OD1]),$(C(F)(F)F)]>>  STAND_6\n\
#[O;D1;$Disconn]S(=O)(=O)c1[cH][cH]c([$([cH]),$(c[CH3])])[cH][cH]1\n\
#Cul *\n\
#[O;D1;$Disconn]S(=O)(=O)c1[cH][cH]c([$([cH]),$(c[CH3])])[cH][cH]1>>  STAND_7\n\
[$O_ONE_CONNECTION;$Disconn]S(=O)(=O)c1[cH][cH]c([$([cH]),$(c[CH3])])[cH][cH]1>>  STAND_7\n\
#[O;D1;$Disconn]P(=O)([OD1])[$([CH3]),$([OD1])]\n\
#Cul *\n\
#[O;D1;$Disconn]P(=O)([OD1])[$([CH3]),$([OD1])]>>  STAND_8\n\
[$O_ONE_CONNECTION;$Disconn]P(=O)([OD1])[$([CH3]),$([OD1])]>>  STAND_8\n\
#[O;D1;$Disconn]C(=O)[CH]=[CH]C(=O)[OD1]\n\
#Cul *\n\
#[O;D1;$Disconn]C(=O)[CH]=[CH]C(=O)[OD1]>>  STAND_9\n\
[$O_ONE_CONNECTION;$Disconn]C(=O)[CH]=[CH]C(=O)[OD1]>>  STAND_9\n\
#[O;D1;$Disconn]C(=O)[CH]([OH])[CH]([OH])C(=O)[OD1]\n\
#Cul *\n\
#[O;D1;$Disconn]C(=O)[CH]([OH])[CH]([OH])C(=O)[OD1]>>  STAND_10\n\
[$O_ONE_CONNECTION;$Disconn]C(=O)[CH]([OH])[CH]([OH])C(=O)[OD1]>>  STAND_10\n\
#[O;D1;$Disconn]C(=O)C(=O)[OD1]\n\
#Cul *\n\
#[O;D1;$Disconn]C(=O)C(=O)[OD1]>>  STAND_11\n\
[$O_ONE_CONNECTION;$Disconn]C(=O)C(=O)[OD1]>>  STAND_11\n\
#[B;X4;$Disconn](F)(F)(F)F\n\
#Cul *\n\
[B;X4;$Disconn](F)(F)(F)F>>  STAND_12\n\
#\n\
#  Bases & cations\n\
#\n\
#[N;D1;$Disconn][$MeEt]\n\
#Cul *\n\
#[N;D1;$Disconn][$MeEt]>>  STAND_13\n\
[$N_ONE_CONNECTION;$Disconn][$MeEt]>>  STAND_13\n\
#[N;D2;$Disconn]([$MeEt])[$MeEt]\n\
#Cul *\n\
#[N;D2;$Disconn]([$MeEt])[$MeEt]>>  STAND_14\n\
[$N_TWO_CONNECTION;$Disconn]([$MeEt])[$MeEt]>>  STAND_14\n\
#[N;D3;$Disconn]([$MeEt])([$MeEt])[$MeEt]\n\
#Cul *\n\
#[N;D3;$Disconn]([$MeEt])([$MeEt])[$MeEt]>>  STAND_15\n\
[$N_THREE_CONNECTION;$Disconn]([$MeEt])([$MeEt])[$MeEt]>>  STAND_15\n\
#[N;+;$Disconn]([$MeEt])([$MeEt])([$MeEt])[$MeEt]\n\
#Cul *\n\
[N;+;$Disconn]([$MeEt])([$MeEt])([$MeEt])[$MeEt]>>  STAND_16\n\
#[N;D2;$Disconn]1[CH2][CH2][O,C&H2,N&D2][CH2][CH2]1\n\
#Cul *\n\
#[N;D2;$Disconn]1[CH2][CH2][O,C&H2,N&D2][CH2][CH2]1>>  STAND_17\n\
[$N_TWO_CONNECTION;$Disconn]1[CH2][CH2][O,C&H2,N&D2][CH2][CH2]1>>  STAND_17\n\
#[N;D1;$Disconn]=C([ND1])[ND1]\n\
#Cul *\n\
#[N;D1;$Disconn]=C([ND1])[ND1]>>  STAND_18\n\
[$N_ONE_CONNECTION;$Disconn]=C([ND1])[ND1]>>  STAND_18\n\
#[n;D2;$Disconn]1[cH][cH][cH][cH][cH]1\n\
#Cul *\n\
[n;D2;$Disconn]1[cH][cH][cH][cH][cH]1>>  STAND_19\n\
#[n;D2;$Disconn]1[cH][nX2][cH][cH]1\n\
#Cul *\n\
[n;D2;$Disconn]1[cH][nX2][cH][cH]1>>  STAND_20\n\
#\n\
#  Neutrals\n\
#\n\
#[N&H2,C&H3;$Disconn]C(=O)[N&H2,C&H3]\n\
#Cul *\n\
[N&H2,C&H3;$Disconn]C(=O)[N&H2,C&H3]>>  STAND_21\n\
#[O;H;$Disconn][$MeEt]\n\
#Cul *\n\
[O;H;$Disconn][$MeEt]>>  STAND_22\n\
#[O;$Disconn]1[CH2][CH2][CH2][CH2]1\n\
#Cul *\n\
[O;$Disconn]1[CH2][CH2][CH2][CH2]1>>  STAND_23\n\
#\n\
#  Discard atoms lacking non-hydrogen connections\n\
#  This is done again to zap things like fluorines\n\
#  that get generated by the processing of \n\
#  fragments such as trifluoroacetate\n\
#  \n\
#[C,N,O,F,Cl,Br,I,2*,3*;D0;$Disconn]\n\
#Cul 1\n\
#[C,N,O,F,Cl,Br,I,2*,3*;D0;$Disconn]>>  STAND_24\n\
[$BlandMet&D0,$C_NO_CONNECTION,$N_NO_CONNECTION,$O_NO_CONNECTION,$HALIDE_NO_CONNECTION,2*,3*;$Disconn]>> STAND_24\n\
#\n\
#------------------------------------------------------------------\n\
#\n\
#  Shift charge on carbocation to adjacent heteroatom if present\n\
#\n\
#[C;+;X3]-[N;X3;v3;!+]\n\
#Chg  1  0\n\
#Chg  2  1\n\
#Bnd  1  2  2\n\
[C;+;X3:1]-[N;X3;v3;!+:2]>>[C:1]=[N+:2] STAND_25\n\
#\n\
#[C;+;X3]-[O,S;X2!+]\n\
#Chg  1  0\n\
#Chg  2  1\n\
#Bnd  1  2  2\n\
[C;+;X3:1]-[O,S;X2!+:2]>>[C:1]=[*:2] STAND_26\n\
#\n\
#------------------------------------------------------------------\n\
#\n\
#  Ylids:  \n\
#  The ylid form of a nitro group renders oxygens non-equivalent\n\
#  and unneccessarily assigns formal charges which can complicate\n\
#  substructural searching.  \n\
#\n\
#[$YLID1][$YLID2]\n\
#Chg  1   0\n\
#Chg  2   0\n\
#Bnd  1   2   2\n\
[$YLID1:1]-[$YLID2:2]>>[*;+0:1]=[*;+0:2] STAND_27\n\
#\n\
#  An uncommon abomination...\n\
#\n\
#[S+2]([O-])[O-]\n\
#Chg  1  0\n\
#Chg  2  0\n\
#Chg  3  0\n\
#Bnd  1  2  2\n\
#Bnd  1  3  2\n\
[S+2:1](-[O-:2])-[O-:3]>>[S+0:1](=[O-0:2])=[O-0:3] STAND_28\n\
#\n\
#  Azides...the ylid canonical forms of these were getting\n\
#  neutralised...until spotted by eagle-eyes of Jens & Andrew.\n\
#[N;!+;X2]=[N;X2;+]=[N;X1;-]\n\
#Chg  2  0\n\
#Chg  3  0\n\
#Bnd  2  3  3\n\
[N;!+;X2:1]=[N;X2;+:2]=[N;X1;-:3]>>[N;+0:1]=[N;+0:2]#[N;+0:3] STAND_29\n\
#-------------------------------------------------------------------\n\
#\n\
#  Render carbon monoxide and isonitriles uncharged with divalent \n\
#  carbon\n\
#\n\
#[C;X1;-]#[$([N;X2;+]),$([O;X1;+])]\n\
#Chg  1   0\n\
#Chg  2   0\n\
#Bnd  1   2   2\n\
[C;X1;-:1]#[$([N;X2;+]),$([O;X1;+]):2]>>[*;+0:1]=[*;+0:2] STAND_30\n\
#------------------------------------------------------------------- \n\
#\n\
#  Neutralise ionised groups; makes no sense physiologically\n\
#  but provides consistency between databases and gets molecules \n\
#  to appropriate starting point for a number of computation methods \n\
#\n\
#  Anions\n\
#[$ANION]\n\
#PRT  1   1\n\
[$ANION:1]>>[*;+0:1][H] STAND_31\n\
#  Cations\n\
#[$CATION]\n\
#PRT  1  -1\n\
[$CATION:1][H]>>[*;+0:1] STAND_32\n\
#--------------------------------------------------------------------\n\
#  \n\
#  Neutralise protonated pyridones which are normally registered\n\
#  as hydroxy canonical form.  These types can prove difficult\n\
#  when fused with aromatic ( see AR-C123277) so require that nitrogen \n\
#  be bonded to an aliphatic atom\n\
#\n\
#  2-Pyridone ( Note full ring specification to get round problems\n\
#               posed by M026088 )\n\
#\n\
#[n;D3;+;!$YLID1]1(-A)c([$OS])[$AR][$AR][$AR][$AR]1\n\
#Bnd  3  4  2\n\
#Chg  1  0\n\
#Hyd  4 -1\n\
[n;D3;+;!$YLID1:1]1(-[A:2])[c:3](-[$OS:4][H:9])[$AR:5][$AR:6][$AR:7][$AR:8]1>>[n;+0:1]1(-[A:2])[c:3](=[*:4])[*:5][*:6][*:7][*:8]1 STAND_33\n\
# \n\
#  4-Pyridone\n\
#[n;D3;+;!$YLID1]1(-A)[$AR][$AR]c([$OS])[$AR][$AR]1\n\
#Bnd  5  6  2\n\
#Chg  1  0\n\
#Hyd  6 -1\n\
[n;D3;+;!$YLID1:1]1(-[A:2])[$AR:3][$AR:4][c:5](-[$OS:6][H:9])[$AR:7][$AR:8]1>>[n;+0:1]1(-[A:2])[*:3][*:4][c:5](=[*:6])[*:7][*:8]1 STAND_34\n\
#--------------------------------------------------------------------\n\
#\n\
#  Indazoles and benzotriazoles:  Convert H(N-2) to H(N-1)\n\
#\n\
#[$NPY]1[n;H;!+][$AR][c;$R2](:a)[c;$R2]1:a\n\
#Hyd  1   1\n\
#Hyd  2  -1\n\
[$NPY:1]1[n;H;!+:2]([H:8])[$AR:3][c;$R2:4](:[a:5])[c;$R2:6]1:[a:7]>>[*:1]1([H:8])[n:2][*:3][c;$R2:4](:[a:5])[c;$R2:6]1:[a:7] STAND_35\n\
#\n\
#--------------------------------------------------------------------\n\
#\n\
#   1,2,4-Triazoles:  Move H on N-4 to N-1/2\n\
#[$NPY]1[$NPY][$CAR][n;H;!+][$CAR]1\n\
#Hyd 1   1\n\
#Hyd 4  -1\n\
[$NPY:1]1[$NPY:2][$CAR:3][n;H;!+:4]([H:6])[$CAR:5]1>>[*:1]1([H:6])[*:2][*:3][n:4][*:5]1 STAND_36\n\
#\n\
#   1,2,3-Triazole:  Move H on N2 to N1 for standardisation... it'll\n\
#                    be dealt with in enumeration step later\n\
#\n\
#[$NPY]1[n;X3;H][$NPY][$CAR][$CAR]1\n\
#Hyd 1   1\n\
#Hyd 2  -1\n\
[$NPY:1]1[n;X3;H:2]([H:6])[$NPY:3][$CAR:4][$CAR:5]1>>[*:1]1([H:6])[n:2][*:3][*:4][*:5]1 STAND_37\n\
#\n\
#--------------------------------------------------------------------\n\
#\n\
#  Hydroxy imines & enols are converted to carbonyl\n\
#\n\
#  Aliphatic situation is easy because don't have\n\
#  to worry about inappropriate bond localisation\n\
#\n\
#[N;X2]=C[O,S;H;X2]\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
#Bnd  1   2   1\n\
#Bnd  2   3   2\n\
[N;X2:1]=[C:2]-[O,S;H;X2:3][H:4]>>[N:1]([H:4])-[C:2]=[*:3] STAND_38\n\
#\n\
#  Aromatic case is more fiddly because aromatic system\n\
#  may not be able to accomodate bond localisation\n\
#\n\
#[N;!R;!+]=c1[n&X3,o,s;!+]c([$OS])[$AR][$AR][$AR]1\n\
#Hyd  1   1\n\
#Hyd  5  -1\n\
#Bnd  1   2   1\n\
#Bnd  4   5   2\n\
[N;!R;!+:1]=[c:2]1[n&X3,o,s;!+:3][c:4](-[$OS:5][H:9])[$AR:6][$AR:7][$AR:8]1>>[N:1]([H:9])-[c:2]1[*:3][c:4](=[*:5])[*:6][*:7][*:8]1 STAND_39\n\
#\n\
#  Enols & thioenols\n\
#[O,S;H;X2]C=C\n\
#Hyd  1  -1\n\
#Hyd  3   1\n\
#Bnd  2   3  1\n\
#Bnd  1   2  2\n\
[H:4][O,S,N;H;X2:1]-[C:2]=[C:3]>>[*:1]=[C:2]-[C:3][H:4] STAND_40\n\
#\n\
#  \n\
#---------------------------------------------------------------------\n\
#\n\
#  Homophthalimides; the non-aromatic (dicarbonyl) tautomer is\n\
#  favored and consequently these are less acidic than \n\
#  hydroxpyridines (see TautHet, 110).  Interesting effect of \n\
#  ring fusion: compare with differing regioselectivity of \n\
#  electrophilic aromatic substitution of reaction pyrrole and\n\
#  indole.  Need to do these BEFORE pyridone analogues\n\
#\n\
#[$OS]c1[$NPY]c([$OS])cc2c1cccc2\n\
#Bnd   1  2  2\n\
#Bnd   2  3  1\n\
#Bnd   4  5  2\n\
#Bnd   4  6  1\n\
#Hyd   1 -1\n\
#Hyd   3  1\n\
#Hyd   5 -1\n\
#Hyd   6  1\n\
[H:14][$OS:1]-[c:2]1[$NPY:3][c:4](-[$OS:5][H:13])[c:6][c:7]2[c:8]1[c:9][c:10][c:11][c:12]2>>[*:1]=[c:2]1-[*:3]([H:14])[c:4](=[*:5])-[c:6]([H:13])[c:7]2[c:8]1[c:9][c:10][c:11][c:12]2 STAND_41\n\
#--------------------------------------------------------------\n\
#  Cyanuric acid & sulfur analogues:\n\
#  TautHet, p138-139\n\
#\n\
#[$NPY]1[$CXH]([$OS])[$NPY][$CXH]([$OS])[$NPY][$CXH]1[$OS]\n\
#Bnd  2   3  2\n\
#Bnd  5   6  2\n\
#Bnd  8   9  2\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
#Hyd  4   1\n\
#Hyd  6  -1\n\
#Hyd  7   1\n\
#Hyd  9  -1\n\
[$NPY:1]1[$CXH:2](-[$OS:3][H:10])[$NPY:4][$CXH:5](-[$OS:6][H:11])[$NPY:7][$CXH:8]1-[$OS:9][H:12]>>[*:1]1([H:10])[*:2](=[*:3])[*:4]([H:11])[*:5](=[*:6])[*:7]([H:12])[*:8]1=[*:9] STAND_42\n\
#---------------------------------------------------------------------\n\
#\n\
#  2,4-Dihydroxypyrimidines & analogues:\n\
#  Note that these are processed before the hydroxypyridines\n\
#  See\n\
#[$NPY]1[$CXH]([$OS])[$NPY][$CXH]([$OS])[$AR][$AR]1\n\
#Bnd  2   3  2\n\
#Bnd  5   6  2\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
#Hyd  4   1\n\
#Hyd  6  -1\n\
[$NPY:1]1[$CXH:2](-[$OS:3][H:9])[$NPY:4][$CXH:5](-[$OS:6][H:10])[$AR:7][$AR:8]1>>[*:1]1([H:9])[*:2](=[*:3])[*:4]([H:10])[*:5](=[*:6])[*:7][*:8]1 STAND_43\n\
#---------------------------------------------------------------------\n\
#\n\
#  2,3-Dihydroxypyrazines & analogues:\n\
#  See TautHet, p 138\n\
#\n\
#[$NPY]1[$CXH]([$OS])[$CXH]([$OS])[$NPY][$CAR][$AR]1\n\
#Bnd  2   3  2\n\
#Bnd  4   5  2\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
#Hyd  5  -1\n\
#Hyd  6   1\n\
[$NPY:1]1[$CXH:2](-[$OS:3][H:9])[$CXH:4](-[$OS:5][H:10])[$NPY:6][$CAR:7][$AR:8]1>>[*:1]1([H:9])[*:2](=[*:3])[*:4](=[*:5])[*:6]([H:10])[*:7][*:8]1 STAND_44\n\
#-----------------------------------------------------------------\n\
#\n\
#  2-Hydroxyquinazolines:  Form amide next to ring junction\n\
#[$NPY]1c([$OS])[$NPY][$AR;$R1][c;$R2](a)[c;$R2]1a\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
#Bnd  2   3  2\n\
[$NPY:1]1[c:2](-[$OS:3][H:10])[$NPY:4][$AR;$R1:5][c;$R2:6]([a:7])[c;$R2:8]1[a:9]>>[*:1]1([H:10])[c:2](=[*:3])[*:4][*:5][c:6]([a:7])[c:8]1[a:9] STAND_45\n\
#  and fix inappropriate amide\n\
#[$NPY]1c(=[O,S])[n;H;!+][$AR;$R1][c;$R2](a)[c;$R2]1a\n\
#Hyd  1   1\n\
#Hyd  4  -1\n\
[$NPY:1]1[c:2](=[O,S:3])[n;H;!+:4]([H:10])[$AR;$R1:5][c;$R2:6]([a:7])[c;$R2:8]1[a:9]>>[*:1]1([H:10])[c:2](=[*:3])[n:4][*:5][c:6]([a:7])[c:8]1[a:9] STAND_46\n\
#-------------------------------------------------------------------\n\
#\n\
#  Hydroxypyridines & analogues\n\
#\n\
#  2-Hydroxypyridines\n\
#[$NPY]1[$CXH]([O,S;H])[$AR][$AR][$AR][$AR]1\n\
#[$NPY]1[$CXH]([O,S;H])[$AR][$AR][$AR]a1\n\
#Bnd  2   3  2\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
[$NPY:1]1[$CXH:2](-[O,S;H:3][H:8])[$AR:4][$AR:5][$AR:6][a:7]1>>[*:1]1([H:8])[*:2](=[*:3])[*:4][*:5][*:6][a:7]1 STAND_47\n\
#\n\
#  4-Hydroxypyridines \n\
#[$NPY]1[$AR][$AR][$CXH]([O,S;H])[$AR][$AR]1\n\
#Bnd  4   5  2\n\
#Hyd  1   1\n\
#Hyd  5  -1\n\
[$NPY:1]1[$AR:2][$AR:3][$CXH:4](-[O,S;H:5][H:8])[$AR:6][$AR:7]1>>[*:1]1([H:8])[*:2][*:3][*:4](=[*:5])[*:6][*:7]1 STAND_48\n\
#--------------------------------------------------------------\n\
#\n\
#  Maleic hydrazides (dihydroxy tautomers will be dealt \n\
#  with by SMARTS for 2-pyridones).  The tautomeric preferences\n\
#  of these species is a consequence of repulsion between \n\
#  nitrogen lone pairs, (a favorite theme of PJ Taylor!)\n\
#  See TautHet, p 124.  Will also deal with hemi-tautomers.\n\
# \n\
#[n;H]1c(=[O,S])ccc(=[O,S])[n;X3]1\n\
#Bnd  2  3  1\n\
#Hyd  1 -1\n\
#Hyd  3  1\n\
[n;H:1]1([H:9])[c:2](=[O,S:3])[c:4][c:5][c:6](=[O,S:7])[n;X3:8]1>>[n:1]1[c:2](-[*:3][H:9])[c:4][c:5][c:6](=[*:7])[n:8]1 STAND_49\n\
#-------------------------------------------------------  \n\
#\n\
#  Hemi-tautomerised species\n\
#\n\
#  Pyrimidine #1\n\
#[$NPY]1[$CXH]([$OS])[n&X3,o&X2,s&X2]c(=[O,S])[$AR][$AR]1\n\
#Bnd  2   3  2\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
[$NPY:1]1[$CXH:2](-[$OS:3][H:9])[n&X3,o&X2,s&X2:4][c:5](=[O,S:6])[$AR:7][$AR:8]1>>[*:1]1([H:9])[*:2](=[*:3])[*:4][c:5](=[*:6])[*:7][*:8]1 STAND_50\n\
#\n\
#  Pyrimidine #2\n\
#[$NPY]1[$CXH]([$OS])[$AR][$AR][n;X3,o&X2,s&X2]c1=[O,S]\n\
#Bnd  2   3  2\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
[$NPY:1]1[$CXH:2](-[$OS:3][H:9])[$AR:4][$AR:5][n;X3,o&X2,s&X2:6][c:7]1=[O,S:8]>>[*:1]1([H:9])[*:2](=[*:3])[*:4][*:5][*:6][c:7]1=[*:8] STAND_51\n\
#\n\
#  Pyrimidine #3\n\
#[$NPY]1[$CXH]([$OS])[n&X3,o&X2,s&X2][$AR][$AR]c1(=[O,S])\n\
#Bnd  2   3  2\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
[$NPY:1]1[$CXH:2](-[$OS:3][H:9])[n&X3,o&X2,s&X2:4][$AR:5][$AR:6][c:7]1(=[O,S:8])>>[*:1]1([H:9])[*:2](=[*:3])[*:4][*:5][*:6][c:7]1(=[*:8]) STAND_52\n\
#\n\
#  Pyrimidine #4\n\
#[$NPY]1[$AR][$AR][$CXH]([$OS])[n&X3,o&X2,s&X2]c1(=[O,S])\n\
#Bnd  4   5  2\n\
#Hyd  1   1\n\
#Hyd  5  -1\n\
[$NPY:1]1[$AR:2][$AR:3][$CXH:4](-[$OS:5][H:9])[n&X3,o&X2,s&X2:6][c:7]1(=[O,S:8])>>[*:1]1([H:9])[*:2][*:3][*:4](=[*:5])[*:6][c:7]1(=[*:8]) STAND_53\n\
#\n\
#  Pyrazine\n\
#[$NPY]1[$CAR]([$OS])c(=[O,S])[n&X3,o&X2,s&X2][$AR][$AR]1\n\
#Bnd  2   3  2\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
[$NPY:1]1[$CAR:2](-[$OS:3][H:9])[c:4](=[O,S:5])[n&X3,o&X2,s&X2:6][$AR:7][$AR:8]1>>[*:1]1([H:9])[*:2](=[*:3])[c:4](=[*:5])[*:6][*:7][*:8]1 STAND_54\n\
#\n\
#--------------------------------------------------------------\n\
#\n\
# Where possible bring together pi-donor & (thio)carbonyl\n\
#\n\
# 4-Pyrimidones & analogues \n\
#\n\
#[O,S;X1]=c1[nX2][$AR][n;H;X3][$AR][$AR]1\n\
#Hyd  3   1\n\
#Hyd  5  -1\n\
[O,S;X1:1]=[c:2]1[nX2:3][$AR:4][n;H;X3:5]([H:8])[$AR:6][$AR:7]1>>[*:1]=[c:2]1[n:3]([H:8])[*:4][n:5][*:6][*:7]1 STAND_55\n\
#\n\
#  4-Hydroxypyridones & analogues\n\
#[O,S;X1]=c1[$AR]c([$OS])[$PiDon][$AR][$AR]1\n\
#Hyd  1   1\n\
#Hyd  5  -1\n\
#Bnd  1   2   1\n\
#Bnd  4   5   2\n\
[O,S;X1:1]=[c:2]1[$AR:3][c:4](-[$OS:5][H:9])[$PiDon:6][$AR:7][$AR:8]1>>[H:9][*:1]-[c:2]1[*:3][c:4](=[*:5])[*:6][*:7][*:8]1 STAND_56\n\
#\n\
#   Oxadiazolones...move NH next to carbonyl\n\
#[o,s]1[nH][$CAR][nX2]c1=O\n\
#Hyd  2  -1\n\
#Hyd  4   1\n\
[o,s:1]1[nH:2]([H:7])[$CAR:3][nX2:4][c:5]1=[O:6]>>[*:1]1[n:2][*:3][n:4]([H:7])[c:5]1=[O:6] STAND_57\n\
#\n\
#   1,2,4-Triazolones\n\
#[O,S&X1]=c1[nX2][$CAR][nH][nH]1\n\
#Hyd  3   1\n\
#Hyd  5  -1\n\
[O,S&X1:1]=[c:2]1[nX2:3][$CAR:4][nH:5]([H:7])[nH:6]1>>[*:1]=[c:2]1[n:3]([H:7])[*:4][n:5][nH:6]1 STAND_58\n\
#\n\
#---------------------------------------------------------------\n\
#\n\
#  Ring-fused analogues of 2-pyrimidone:  Ensure that NH is placed\n\
#  next to ring fusion to minimise disruption of aromaticity\n\
#\n\
#O=c1[nH][$AR][$CARFUS][$CARFUS][nX2]1\n\
#Hyd  3  -1\n\
#Hyd  7   1\n\
[O:1]=[c:2]1[nH:3]([H:8])[$AR:4][$CARFUS:5][$CARFUS:6][nX2:7]1>>[O:1]=[c:2]1[n:3][*:4][*:5][*:6][n:7]1[H:8] STAND_59\n\
#\n\
#---------------------------------------------------------------\n\
#  Fused 6/5 systems\n\
#\n\
#  5-Oxopyrazolo[1,5-a]pyrimidines & (des)aza analogues\n\
#  (see TautHet, p 538)\n\
#[$NPY]1c([$OS])[$AR][$AR][n;D3;!+]2[$AR][$AR][$AR]c12\n\
#Bnd  2  3  2\n\
#Hyd  1  1\n\
#Hyd  3 -1\n\
[$NPY:1]1[c:2](-[$OS:3][H:11])[$AR:4][$AR:5][n;D3;!+:6]2[$AR:7][$AR:8][$AR:9][c:10]12>>[*:1]1([H:11])[c:2](=[*:3])[*:4][*:5][n:6]2[*:7][*:8][*:9][c:10]12 STAND_60\n\
#\n\
#  Pyrazolo[1,5-c]pyrimidines & (des)aza analogues\n\
#  (See TautHet, p538-539)\n\
#[$OS]c1[$NPY][$AR][$AR]c2[n;D3;!+]1[$AR][$AR][$AR]2\n\
#Bnd  1  2  2\n\
#Hyd  1 -1\n\
#Hyd  3  1\n\
[H:11][$OS:1]-[c:2]1[$NPY:3][$AR:4][$AR:5][c:6]2[n;D3;!+:7]1[$AR:8][$AR:9][$AR:10]2>>[*:1]=[c:2]1[*:3]([H:11])[*:4][*:5][c:6]2[n:7]1[*:8][*:9][*:10]2 STAND_61\n\
#\n\
#  7-Oxopyrazolo[1,5-a]pyrimidines\n\
#  TautHet p538 notes that these exist as a mixture of \n\
#  keto & enol tautomers in the solid state.  Convert to \n\
#  keto for now; maybe check out with ab initio calculation\n\
#  at an idle moment.\n\
#[$OS]c1[$CAR][$AR][$NPY]c2[n;D3;!+]1[$AR][$AR][$AR]2\n\
#Bnd  1  2  2\n\
#Hyd  1 -1\n\
#Hyd  5  1\n\
[H:11][$OS:1]-[c:2]1[$CAR:3][$AR:4][$NPY:5][c:6]2[n;D3;!+:7]1[$AR:8][$AR:9][$AR:10]2>>[*:1]=[c:2]1[*:3][*:4][*:5]([H:11])[c:6]2[n:7]1[*:8][*:9][*:10]2 STAND_62\n\
#\n\
#   Pyrrolopyridines (nomenclature unclear) & analogues \n\
#\n\
#[$OS]c1[$CAR][$AR][$NPY][n;D3;!+]2c1[$AR][$AR][$AR]2\n\
#Bnd  1  2  2\n\
#Hyd  1 -1\n\
#Hyd  5  1\n\
[H:11][$OS:1]-[c:2]1[$CAR:3][$AR:4][$NPY:5][n;D3;!+:6]2[c:7]1[$AR:8][$AR:9][$AR:10]2>>[*:1]=[c:2]1[*:3][*:4][*:5]([H:11])[n:6]2[c:7]1[*:8][*:9][*:10]2 STAND_63\n\
#\n\
#--------------------------------------------------------------\n\
#\n\
#  Fused 6-ring with 3-connected nitrogen as one of ring\n\
#  fusion atoms.  Note the use of $OXO to get round the \n\
#  M032099 problem and the use of these SMARTS after the\n\
#  SMARTS written explicitly for 6/5 fused systems\n\
#\n\
#[$NPY]1c([$OS])[n;$R2]([$OXO])[c;$R2][$AR][$AR]1\n\
#Hyd  1  1\n\
#Hyd  3 -1\n\
#Bnd  2  3  2\n\
[$NPY:1]1[c:2](-[$OS:3][H:9])[n;$R2:4]([$OXO:5])[c;$R2:6][$AR:7][$AR:8]1>>[*:1]1([H:9])[c:2](=[*:3])[n:4]([*:5])[c;$R2:6][*:7][*:8]1 STAND_64\n\
#\n\
#[$NPY]1c([$OS])[c;$R2][n;$R2]([$OXO])[$AR][$AR]1\n\
#Hyd  1  1\n\
#Hyd  3 -1\n\
#Bnd  2  3  2\n\
[$NPY:1]1[c:2](-[$OS:3][H:9])[c;$R2:4][n;$R2:5]([$OXO:6])[$AR:7][$AR:8]1>>[*:1]1([H:9])[c:2](=[*:3])[c:4][n:5]([*:6])[*:7][*:8]1 STAND_65\n\
#\n\
#[$NPY]1[$AR][$AR]c([$OS])[n;$R2]([$OXO])[c;$R2]1\n\
#Hyd  1  1\n\
#Hyd  5 -1\n\
#Bnd  4  5  2\n\
[$NPY:1]1[$AR:2][$AR:3][c:4](-[$OS:5][H:9])[n;$R2:6]([$OXO:7])[c;$R2:8]1>>[*:1]1([H:9])[*:2][*:3][c:4](=[*:5])[n:6]([*:7])[c:8]1 STAND_66\n\
#\n\
#[$NPY]1[$AR][$AR]c([$OS])[c;$R2][n;$R2]1[$OXO]\n\
#Hyd  1  1\n\
#Hyd  5 -1\n\
#Bnd  4  5  2\n\
[$NPY:1]1[$AR:2][$AR:3][c:4](-[$OS:5][H:9])[c;$R2:6][n;$R2:7]1[$OXO:8]>>[*:1]1([H:9])[*:2][*:3][c:4](=[*:5])[c:6][n:7]1[*:8] STAND_67\n\
#-------------------------------------------------------------\n\
#\n\
#  nc-XH isolated between c(=O) and [n;X3]\n\
#\n\
#[n;X3][$CXH]([$OS])[$NPY]c=[A]\n\
#Bnd  2  3  2\n\
#Hyd  3 -1\n\
#Hyd  4  1\n\
[n;X3:1][$CXH:2](-[$OS:3][H:7])[$NPY:4][c:5]=[A:6]>>[n:1][*:2](=[*:3])[*:4]([H:7])[c:5]=[*:6] STAND_68\n\
#\n\
#-------------------------------------------------------------  \n\
#\n\
#  5-Rings:  aim for NH/C=O where possible...later on we'll \n\
#  enumerate those systems which appear finely balanced\n\
#\n\
#  Heteroatoms 1,2 with 3-(thio)hydroxy\n\
#[$OS]c1[$NPY][o,s,n&X3&!+][$AR][$AR]1\n\
#Bnd  1  2  2\n\
#Hyd  1 -1\n\
#Hyd  3  1\n\
[H:7][$OS:1]-[c:2]1[$NPY:3][o,s,n&X3&!+:4][$AR:5][$AR:6]1>>[*:1]=[c:2]1[*:3]([H:7])[*:4][*:5][*:6]1 STAND_69\n\
#\n\
#  Heteroatoms 1,2 with 5-(thio)hydroxy \n\
# \n\
#[$OS]c1[$AR][$AR][$NPY][o,s,n&X3&!+]1\n\
#Bnd  1  2  2\n\
#Hyd  1 -1\n\
#Hyd  5  1\n\
[H:7][$OS:1]-[c:2]1[$AR:3][$AR:4][$NPY:5][o,s,n&X3&!+:6]1>>[*:1]=[c:2]1[*:3][*:4][*:5]([H:7])[*:6]1 STAND_70\n\
#\n\
#  Heteroatoms 1,3 with 2-(thio)hydroxy\n\
#\n\
#[$NPY]1c([$OS])[o,s,n&X3&!+][$AR][$AR]1\n\
#Bnd  2  3  2\n\
#Hyd  1  1\n\
#Hyd  3 -1\n\
[$NPY:1]1[c:2](-[$OS:3][H:7])[o,s,n&X3&!+:4][$AR:5][$AR:6]1>>[*:1]1([H:7])[c:2](=[*:3])[*:4][*:5][*:6]1 STAND_71\n\
#\n\
#  Heteroatoms 1,2 with 5-carbonyl and saturated at C-4 as\n\
#  exemplified by M478560 & M644055\n\
#\n\
#[O,S&X2,N&X3;!+]1[NX2]=C[C;H,H2]C1=[O,S]\n\
#Bnd  2  3  1\n\
#Bnd  3  4  2\n\
#Hyd  2  1\n\
#Hyd  4 -1\n\
[O,S&X2,N&X3;!+:1]1[NX2:2]=[C:3]-[C;H,H2:4]([H:7])[C:5]1=[O,S:6]>>[*:1]1[N:2]([H:7])-[C:3]=[C:4][C:5]1=[*:6] STAND_72\n\
#  \n\
#--------------------------------------------------------------\n\
#\n\
#  These will switch benzotriazole or benzimidazole so that\n\
#  N-H points towards O/N lone pair rather than another N-H\n\
#  (Note problems caused by deuterium bonded to nitrogen...adopt\n\
#   Strategy of Masterly Inaction advocated by JJM) \n\
#\n\
#[$Acc,$NoHB][a;$R2]1[$NPY][$AR][$NHnotDeu][a;$R2]1[$Don]\n\
#Hyd  3   1\n\
#Hyd  5  -1\n\
[$Acc,$NoHB:1][a;$R2:2]1[$NPY:3][$AR:4][$NHnotDeu:5]([H:8])[a;$R2:6]1[$Don:7]>>[*:1][*:2]1[*:3]([H:8])[*:4][*:5][*:6]1[*:7] STAND_73\n\
#\n\
#[$Acc][a;$R2]1[$NPY][$AR][$NHnotDeu][a;$R2]1[$Don,$NoHB]\n\
#Hyd  3   1\n\
#Hyd  5  -1\n\
[$Acc:1][a;$R2:2]1[$NPY:3][$AR:4][$NHnotDeu:5]([H:8])[a;$R2:6]1[$Don,$NoHB:7]>>[*:1][*:2]1[*:3]([H:8])[*:4][*:5][*:6]1[*:7] STAND_74\n\
#\n\
#--------------------------------------------------------------\n\
#\n\
#  7-Azaindanes\n\
#  Place NH in 5-ring \n\
#[n;H;X3]1[$CAR][$CAR][$CAR]c2c1[nX2][$CAR][$CAR]2\n\
#Hyd  1  -1\n\
#Hyd  7   1\n\
[H:10][n;H;X3:1]1[$CAR:2][$CAR:3][$CAR:4][c:5]2[c:6]1[nX2:7][$CAR:8][$CAR:9]2>>[n:1]1[*:2][*:3][*:4][c:5]2[c:6]1[n:7]([H:10])[*:8][*:9]2 STAND_75\n\
#\n\
#--------------------------------------------------------------\n\
#\n\
#  7-rings \n\
#  Note that the enol M064178 trashed the enol SMARTS\n\
#  so currently we\'re leaving these alone.\n\
#  \n\
#    Amides:\n\
#[n;X2;$r7]1[c;$r7]([$OS])[$AR][$AR][$AR][$AR][$AR]1\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
#Bnd  2   3  2\n\
[n;X2;$r7:1]1[c;$r7:2](-[$OS:3][H:9])[$AR:4][$AR:5][$AR:6][$AR:7][$AR:8]1>>[n:1]1([H:9])[c:2](=[*:3])[*:4][*:5][*:6][*:7][*:8]1 STAND_76\n\
#\n\
#---------------------------------------------------------------\n\
#\n\
#  Move acidic hydrogen of tetrazole from N2 to N1 (i.e next to\n\
#  carbon).\n\
#c1[$NPY][n;H][$NPY][$NPY]1\n\
#HYD    3   -1\n\
#HYD    2    1\n\
[c:1]1[$NPY:2][n;H:3]([H:6])[$NPY:4][$NPY:5]1>>[c:1]1[*:2]([H:6])[n:3][*:4][*:5]1 STAND_77\n\
#-----------------------------------------------------------------\n\
#\n\
#  Move substituent to imine nitrogen for amidines and analogues\n\
#[NH]=C-[NH]-*\n\
#Hyd  1   1\n\
#Hyd  3  -1\n\
#Bnd  1   2   1\n\
#Bnd  2   3   2\n\
[NH:1]=[C:2]-[NH:3]([H:5])-[*:4]>>[H:5][NH:1]-[C:2]=[NH:3]-[*:4] STAND_78\n\
#\n\
#-----------------------------------------------------------------\n\
#AGL Extra\n\
# Move NH from aromatic rings to exocyclic\n\
[nH!$([nH]c=O)!$([nH]aac=O)!$([nH]aaaac=O):1]([H:4])@[c:2]=[N:3]>>[n:1][*:2]-[N:3][H:4] STAND_79\n\
[nH!$([nH]c=O)!$([nH]aac=O)!$([nH]aaaac=O):1]([H:4])@[AR:5]@[AR:6]@[c:2]=[N:3]>>[n:1][a:5][a:6][c:2]-[N:3][H:4] STAND_80";

} // namespace DACLIB

#endif // TAUT_STANDARDISE_DEFAULT_SMIRKS_H
